<span item_type="fundamental" item_id="35e4328410b13ae0acd98e8752ae7f77" counter_id="ST/US/SCNX" env="prod"></span><span item_type="announcement" item_id="548607783958682753" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 0.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.48.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Revenues</strong>: For the three months ended June 30, 2025, revenues were $0, compared to $18,699 for the same period in 2024. For the six months ended June 30, 2025, revenues were $10,258, compared to $18,699 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2025, net loss was - $6,720,573, compared to - $1,833,902 for the same period in 2024. For the six months ended June 30, 2025, net loss was - $9,784,570, compared to $19,412,131 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended June 30, 2025, were $5,157,906, compared to $1,494,988 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $8,729,896, compared to $6,987,959 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was - $4,990,704, compared to - $5,967,718 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was $4,697,999, compared to - $13,896,011 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development Expenses</strong>: For the three months ended June 30, 2025, research and development expenses were $843,549, and for the six months ended June 30, 2025, they were $1,418,228.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Scienture aims to advance product candidates through clinical studies and toward commercialization, drive growth and profitability, continue to grow its pipeline, and target strategic business development opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company completed the sale of its subsidiaries, IPS, Softell, and Bonum Health, Inc., to Tollo, as part of a strategic realignment to focus on its core operations and accelerate growth in the Branded and Specialty Pharma markets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li><strong>Strategic Realignment</strong>: The divestitures are intended to streamline operations, optimize the portfolio, and facilitate high-growth commercial and strategic product development activities at Scienture.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1382574/000164117225023121/form10-q.htm"></span></li></ul>

Scienture | 10-Q: FY2025 Q2 Revenue: USD 0